Executive summary
US Patent 8,512,717 is drafted as a formulation patent that claims a specific ophthalmic solution platform: ketorolac at 0.01% to 1.0% w/v, buffered to pH 6 to 8, and thickened for ocular retention using a defined bimodal carboxymethyl cellulose (CMC) system (medium + high molecular weight CMC in a weight ratio 0.25 to 4, total CMC 0.1% to 2.0% w/v). Claim scope hinges on (i) the ketorolac concentration band, (ii) the dual CMC molecular-weight mix and ratio, (iii) viscosity/retention tied to “viscosity greater than human tear fluid,” and (iv) ophthalmic compatibility via pH 6 to 8. The practical freedom-to-operate (FTO) risk for generics or reformulation entrants is concentrated on avoiding that CMC mix (ratio and MW split), avoiding that ketorolac strength range, and avoiding the pH window, unless an alternative retention polymer and formulation strategy is used.
US Patent 8,512,717 scope: what is claimed for ketorolac ophthalmic retention and pH?
What is the core claim scope of US 8,512,717 (claims 1-6)?
The independent claim (Claim 1) is a “comprising” style formulation claim for a topical ophthalmic solution for ophthalmic inflammation, with the following required elements:
- Active: ketorolac at 0.01% to 1.0% w/v
- Retention/viscosity system: a retention component that yields viscosity greater than human tear fluid, where the retention component consists of a mixture of medium MW CMC + high MW CMC with:
- weight ratio (medium:high) between 0.25 and 4
- total amount 0.1% to 2.0% w/v
- Ophthalmic carriers and salts: water; sodium chloride; a buffer
- pH adjustment: sodium hydroxide and hydrochloric acid to reach pH about 6 to about 8
Claim 2 narrows the polymer identity: the medium/high MW CMC are specifically sodium carboxymethyl cellulose.
Claim 3 is an alternate independent claim emphasizing the same composition constraints with explicit “consisting of” language (water carrier, ketorolac strength band, CMC mixture and ratio, sodium chloride, buffer, pH 6 to 8).
Claim 4 is a use-framed claim (treatment of pain and inflammation) but with the same formulation boundaries as Claim 3.
Claim 5 constrains the pH-adjusting salts to 1 N sodium hydroxide and hydrochloric acid.
Claim 6 sets a target pH: about 6.8.
Claim construction consequences (practical)
- The CMC system is the claim’s main gatekeeper. If a product uses only one MW CMC grade, or uses a different retention system (e.g., HPMC, PVP, carbomer, hyaluronic acid, propylene glycol alginate), it can fall outside the “mixture of medium and high MW CMC with weight ratio 0.25 to 4” limitation.
- The polymer ratio is a tunable but litigious parameter. A design-around can be to move the medium:high ratio outside 0.25 to 4.
- The concentration bands are also tunable. Ketorolac 0.01% to 1.0% w/v and total CMC 0.1% to 2.0% w/v define quantitative fences.
- “Viscosity greater than human tear fluid” is a functional limiter, but still tethered to the defined retention component. Even if viscosity is measured, the claim ties viscosity to the CMC mixture described.
- pH is constrained twice: generally (6 to 8) and also in dependent claims via specific adjustment strength (Claim 5) and specific pH value (Claim 6).
How do “consisting of” vs “consisting essentially of” affect infringement risk?
Claims 1 and 3-6 use “consisting of” language in the provided claim text. That typically narrows permissible additives to those listed (and sometimes to impurities). Practically, that raises risk for entrants that include additional retention agents, additional buffering systems, or additional solubilizers beyond what is enumerated. However, since the claims list “buffer” without specifying species, typical ophthalmic buffers may still be argued as encompassed if they meet functional pH and composition. The strongest literal hook remains the CMC mix and its defined ratio and amount.
What is the technical “retention component” limitation and why it matters?
The retention component is not generic “thickener.” It must be:
- A mixture of medium molecular weight CMC and high molecular weight CMC
- Weight ratio: 0.25 to 4
- Total: 0.1% to 2.0% w/v
- Yielding viscosity greater than human tear fluid
For FTO and litigation positions, this means the relevant technical evidence typically centers on:
- polymer grade selection (MW class assignment),
- polymer ratio by weight,
- total wt/wt% loading of the polymer mixture, and
- measured rheology/viscosity compared to human tear fluid.
How many patents cover ketorolac ophthalmic inflammation solutions with CMC retention systems?
What is the likely patent landscape around ketorolac topical ophthalmics?
US 8,512,717 is a formulation patent that sits in a dense cluster of ophthalmic product IP: active ingredient drug patents (composition/derivatives), manufacturing/process patents, and formulation patents that differentiate by:
- viscosity enhancement and ocular retention polymers,
- buffering systems and pH,
- tonicity (sodium chloride, osmolarity targets),
- preservative system (often a separate patent family).
Because the provided prompt supplies only the claims (and not the full patent document data or related US family list), an accurate enumerated landscape cannot be completed without introducing uncited or speculative patent numbers.
Where does US 8,512,717 likely fit among common ketorolac ophthalmic formulation themes?
From the claim language alone, the patent maps to a specific differentiation axis:
- Retention mechanism: dual MW CMC mixture, not a single polymer grade and not a non-CMC polymer.
- pH window: ophthalmic-typical but specifically constrained to 6–8.
- Active band: ketorolac 0.01%–1.0% w/v.
This makes it more similar to “platform” formulation patents than to narrow process patents, because the claim protects the formulation recipe rather than a manufacturing step.
Which design-arounds can avoid infringement of US 8,512,717 (CMC ratio, MW split, pH, ketorolac strength)?
What happens if a product uses only one molecular weight CMC?
If an accused product uses only medium MW CMC or only high MW CMC, it can avoid the claim’s requirement that the retention component “consists of a mixture of medium molecular weight carboxymethyl cellulose and high molecular weight carboxymethyl cellulose” with a defined weight ratio. That is the cleanest literal design-around, assuming the rest of the formulation does not independently satisfy the remaining limitations via some other retained component (which the claim text does not allow since the retention component “consists of” the bimodal CMC mixture).
What happens if the medium:high MW CMC weight ratio is outside 0.25 to 4?
A ratio outside 0.25–4 can fall outside Claim 1/3’s ratio limitation. This design-around depends on:
- how MW “class” is determined for the grades,
- how the mixture ratio is calculated (as-manufactured vs. as-tested),
- and whether the product’s ratio falls in or out of the claimed band.
What happens if ketorolac concentration is outside 0.01% to 1.0% w/v?
Moving the active outside that band can avoid the active concentration limitation. For ophthalmic ketorolac products, real-world strengths may cluster around common commercial formulations. If a commercial competitor stays within the band, it inherits risk from the remaining limitations.
What happens if pH is outside about 6 to about 8?
A pH outside the claimed range can avoid literal infringement. Dependent Claim 6 also targets a specific pH (about 6.8). Dependent Claim 5 adds a constraint on the strength (1 N) of titration acids/bases, which is narrower.
What happens if a different retention polymer replaces CMC?
Substituting retention polymers (e.g., hyaluronic acid, carbomer, HPMC, polyethylene glycol derivatives, PVP) is likely the strongest strategy if the formulation is engineered so the retention component is not the “mixture of medium and high MW CMC” required by the claims. Because Claim 1 specifies the retention component’s composition, an alternative polymer system can avoid the retention component limitation.
How strong is the patent estate for US 8,512,717 in enforcement terms?
What makes US 8,512,717 enforceable: quantitative limits and defined polymer architecture
Enforcement strength typically increases when claims include:
- multiple quantitative restrictions (ketorolac %, total CMC %, ratio range),
- polymer identity limitations (sodium CMC in Claim 2),
- pH constraints (6–8 and specific 6.8),
- and functional viscosity language tied to the defined retention component.
US 8,512,717 has that structure: it does not simply cover “CMC-containing” products. It covers a specific CMC mixture architecture and dosage banding.
What reduces enforceability: interpretation of “viscosity greater than human tear fluid”
Functional limitations can create evidence disputes:
- What reference measure is used for “human tear fluid”?
- Under what conditions is viscosity measured (temperature, shear rate, device)?
- Is “viscosity greater than human tear fluid” directly demonstrable at all times during shelf-life?
Even with those challenges, the claim ties the functional viscosity to the specified retention component, so most accused products that match the CMC architecture will likely be forced to address viscosity comparatives in technical evidence.
What are the key infringement scenarios for ketorolac ophthalmic generics and reformulations?
Could a generic “ketorolac + CMC” product fall within the claim?
Yes if the product matches all key limitations:
- ketorolac concentration within 0.01%–1.0% w/v,
- total medium+high MW sodium CMC within 0.1%–2.0% w/v,
- medium:high MW CMC ratio between 0.25 and 4,
- pH about 6–8, and
- retention component effectively consisting of that bimodal CMC mixture.
Which scenario is lowest risk (typical FTO view)?
A formulation that uses:
- a non-CMC retention system, or
- a single CMC MW grade, or
- CMC ratio outside 0.25–4,
- and/or pH outside 6–8,
is structurally less likely to be captured literally.
What is the Orange Book status of ketorolac ophthalmic products tied to US 8,512,717?
What Orange Book listings are implicated by this patent?
The prompt does not provide the drug name(s), NDA/ANDA numbers, Orange Book listing identifiers, or patent-to-product mappings. Without those specifics, an Orange Book status determination cannot be produced in a complete and accurate manner.
What patent litigation and Paragraph IV challenges affect US 8,512,717?
Which companies have challenged or litigated this patent?
The prompt provides only claim text for US 8,512,717. It does not provide litigation captions, Paragraph IV filings, trial court dockets, CAFC outcomes, or settlement dates. A complete and accurate litigation landscape cannot be generated from the provided information alone.
Timeline: when does US 8,512,717 expire and what term adjustments apply?
When does US 8,512,717 lose exclusivity?
The prompt does not provide the patent’s filing date, priority date, issue date, maintenance status, or any patent term adjustment (PTA) data. Without those, an accurate expiration/exclusivity timeline cannot be calculated.
Key claim charts: how to map each claim element to an accused formulation
Claim 1 element-by-element mapping checklist
- Ophthalmic solution for ophthalmic inflammation (human or animal)
- Ketorolac: 0.01% to 1.0% w/v
- Retention/viscosity: viscosity greater than tear fluid
- Retention component consists of mixture of:
- medium MW CMC
- high MW CMC
- Weight ratio medium:high between 0.25 and 4
- Total CMC amount 0.1% to 2.0% w/v
- Sodium hydroxide and hydrochloric acid used to adjust pH
- pH about 6 to about 8
- Sodium chloride present
- A buffer present
- Water carrier
Dependent claims mapping
- Claim 2: CMC must be sodium carboxymethyl cellulose (not just any CMC salt)
- Claim 3: same recipe as claim 1 but stresses carrier water and “consisting of” list; also removes “retention component” wording and replaces with a “mixture” requirement
- Claim 4: use for pain and inflammation; same composition limits
- Claim 5: acids/bases are 1 N
- Claim 6: pH about 6.8
Key Takeaways
- US 8,512,717 protects a ketorolac ophthalmic solution defined by a dual MW sodium CMC retention architecture: total CMC 0.1%–2.0% w/v and medium:high MW ratio 0.25–4, plus pH about 6–8.
- The main literal infringement levers are the CMC mixture composition (ratio and MW split) and the pH and ketorolac concentration bands.
- Best literal design-arounds are replacing CMC with a different retention polymer, using only one CMC molecular weight class, moving the ratio outside 0.25–4, or moving pH outside 6–8.
- The strongest evidentiary focus in litigation would typically be polymer grade/MW classification, mixture ratio and loading, and viscosity measurements relative to tear fluid reference conditions.
FAQs
-
Does a ketorolac ophthalmic solution with any CMC grade infringe US 8,512,717?
Not if it does not use the claimed dual MW CMC mixture with the required ratio range and loading, or if pH and ketorolac concentration fall outside the claimed windows.
-
Can a formulation avoid Claim 1 by changing only the pH within 6–8?
No. Claim 1 requires pH about 6 to about 8; dependent Claim 6 is specific to about 6.8.
-
What is the most sensitive parameter for design-around: CMC ratio or CMC total concentration?
Both. The claims require both total CMC 0.1%–2.0% w/v and medium:high ratio 0.25–4.
-
Is “viscosity greater than human tear fluid” the primary infringement trigger?
It is a functional limitation, but it is tightly tied to the specific retention component defined as the dual MW CMC mixture.
-
Do method-of-use patents matter more than formulation patents for this asset?
For this patent specifically, the formulation limitations dominate because the independent claims require the full composition recipe; the “pain and inflammation” framing is secondary.
References
- Provided patent claim text for US Patent 8,512,717 (claims 1-6).
